News

Latest news

Hide mandatory notifications of trade

Mandatory notification of trades - New investors

(Oslo, Norway, 9 September 2016) Mandatory Notification of trades

STOCK EXCHANGE ANNOUNCEMENT

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES

Bionor Pharma ASA – Mandatory notification of trades

Reference is made to the stock exchange notice dated 18 August 2016 regarding a private placement of 525,000,000 new shares at subscription price of NOK 0.10 per share ("Private Placement") in Bionor Pharma ASA ("Bionor", ticker "BIONOR"), and the extraordinary general meeting ("EGM") of Bionor held today in which the Private Placement was resolved by Bionor. At the EGM the following, amongst others, have subscribed for and been allocated new shares in Bionor as follows:

• Ferncliff Listed Dai AS, 270,000,000 shares representing 31.37% of the issued shares and votes in Bionor following completion of the Private Placement
• Trojan AS, 100,000,000 shares representing 11.62 % of the issued shares and votes in Bionor following completion of the Private Placement
• Cipriano AS, 50,000,000 shares representing 5.81 % of the issued shares and votes in Bionor following completion of the Private Placement

Ferncliff Listed Dai AS is controlled by Øystein Stray Spetalen and Cipriano AS is controlled by Einar J. Greve. At the EGM, Einar J. Greve was elected as a new Chairman of the Board of Directors of Bionor, and Øystein Stray Spetalen was elected as a new board member. Both elections are effective from the day after the date of approval by the Financial Supervisory Authority of Norway of the prospectus regarding listing of the shares issued in the Private Placement and a contemplated rights offering.

None of the shareholders above or their respective related persons hold any other shares or rights to shares in Bionor.

This information is subject to the disclosure requirements set out in section 4-3 of the Norwegian Securities Trading Act.

Further information
Per S. Thoresen, Chairman of the Board of Directors, +47 906 14 620
Unni Hjelmaas, Acting CEO, +47 915 19 651, uh@bionorpharma.com

Link to announcement in pdf